Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

A sortable and searchable table of PMA supplements approved by FDA in calendar year 2016, updated monthly. Thirty-day notices excluded. Latest update: approvals through May 31.

Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.